Abstract library

11 results for "Ferolla".
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#569 Lack of Accuracy of Circulating Chromogranin A in the Preoperative Diagnosis of Lung Neuroendocrine Tumors
Introduction: While the role of the circulating neuroendocrine (NE) marker Chromogranin A (CgA) in the clinical management of GEP NET has been extensively discussed, the same role in thoracic NE tumors (TNET) remains to be better clarified.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Piero Ferolla
#570 Lymph-Nodal Merkel Cell Carcinoma (MCC) in the Absence of Primary Tumor: Regression of the Primary or Lymph-Nodal Primitivity? Report of a Series with Favorable Prognostic Behavior
Introduction: MCC is a rare cutaneous neuroendocrine neoplasm with aggressive behavior, a high recurrence rate and, generally, poor prognosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Diego Ferone
#586 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2.
Conference:
Category: Clinical
Presenting Author: Antongiulio Faggiano
#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Valeria Ramundo
#749 Natural History of Atypical Carcinoid of Lung After Surgery
Introduction: The natural history of atypical carcinoid (AC) is poorly known.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Francesca Marciello
#1139 Role of Enteroclysis MDTC in the Diagnosis and Follow-Up of Ileal Neuroendocrine Tumors
Introduction: Among all the well differentiated neuroendocrine tumors (NET) those originating from ileum present the more relevant diagnostic difficulties and remain therefore occult in a relevant percentage of cases in all the stages
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Daniele Maiettini
#1538 Safety of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial
Introduction: Dose escalation (or interval reduction) of somatostatin analogs (SSAs) is a rather common strategy for patients (pts) with progressive metastatic neuroendocrine tumors (NETs). However, to date, no systematic prospective studies have been carried out to evaluate safety and efficacy of this treatment schedule in NETs.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD, PhD Manuela Albertelli
#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi
#1804 Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT
Introduction: In phase 3 CLARINET study, LAN 120mg every 28 days significantly prolonged progression-free survival (PFS) vs placebo in pts with well-differentiated metastatic enteropancreatic NETs, but limited data exist for somatostatin analogues in advanced lung/thymic NETs. Evidence that TMZ may be active in thoracic NETs is mainly retrospective.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Piero Ferolla